2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Bioinformatics, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Generative AI, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, CLL, Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

2627 Utilization of and spending on CAR-T cell therapies across public and private payers

Shelley Anne Jazowski, PhD, MPH, Grace Castle2, William Wood, MD, MPH3, Stacie Dusetzina, PhD4
1 Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
2 Vanderbilt University School of Medicine, Nashville, Tennessee, United States
3 University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, United States
4 Vanderbilt University School of Medicine, Nashville, Tennessee, United States

Introduction

Chimeric antigen receptor (CAR)-T cell therapies are transforming the treatment paradigm for relapsed/refractory hematologic malignancies. Real-world studies have begun to document spending on CAR-T cell therapies; however, this research often focuses on a single cancer or payer and predates the FDA approval of many of these innovative therapies. To provide a more comprehensive understanding of CAR-T cell therapy adoption in different care settings, we examined trends in patients’ use of and health plan and enrollee spending on CAR-T cell therapies across public and private payers.

Methods

Using MarketScan Commercial, Supplemental Medicare, and Multi-State Medicaid databases, we identified patients initiating CAR-T cell therapy from January 2017 to November 2024. Patients were required to be continuously enrolled in coverage in the 30 days before and after CAR-T cell therapy infusion. We used Healthcare Common Procedure Coding System codes and International Classification of Diseases, Tenth Revision, Procedure Coding System codes to identify outpatient and inpatient claims for six commercially-available CAR-T cell therapies: brexucabtagene autoleucel, lisocabtagene maraleucel, ciltacabtagene autoleucel, axicabtagene ciloleucel, tisagenlecleucel, and idecabtagene vicleucel. Since CAR-T cell therapy involves care pre- and post-infusion, we assessed health plan and enrollee spending on CAR-T cell therapy, as well as outpatient and inpatient services in the 30 days before and after infusion. Spending estimates were inflation adjusted to 2024 dollars using the Consumer Price Index for all Urban Consumers.

Results

Among 533 patients (75.2% commercial; 13.3% Medicare; 11.4% Medicaid) initiating CAR-T cell therapies, axicabtagene ciloleucel was the most common treatment (38.8%; 44.4% commercial; 11.3% Medicare; 34.4% Medicaid) and brexucabtagene autoleucel was the least common treatment (3.2%; 2.5% commercial; 1.4% Medicare; 9.8% Medicaid). Axicabtagene ciloleucel was primarily received in the inpatient setting (88.9%; 89.9% commercial; 100.0% Medicare; 76.2% Medicaid), whereas tisagenlecleucel had the highest initiation rates in the outpatient setting (69.7%; 65.9% commercial; 0.0% Medicare; 82.6% Medicaid).

Approximately 77.0% (79.3% commercial; 84.5% Medicare; 55.7% Medicaid) and 23.0% (20.7% commercial; 15.5% Medicare; 44.3% Medicaid) of patients initiated CAR-T cell therapies in the inpatient and outpatient settings, respectively. Of those initiating CAR-T cell therapies in the outpatient setting, 14.9% and 41.3% were admitted to the inpatient setting within 3 and 7 days of infusion, respectively. Inpatient admission rates were the highest among patients receiving brexucabtagene autoleucel (3 days: 50.0%; 7 days: 100.0%) and those covered by Medicare (3 days: 18.2%; 7 days: 72.7%).

Health plans and enrollees spent $294.2 million on CAR-T cell therapy and associated care, of which 82.3% was attributed to CAR-T cell therapy infusions. Average spending on CAR-T cell therapy was higher among patients initiating treatment in the inpatient setting ($458,312 versus $439,591), whereas average spending on CAR-T cell therapy and associated care was higher among those receiving infusions in the outpatient setting ($571,328 versus $546,237). Among therapy initiated in the inpatient and outpatient settings, Medicaid patients had the highest average spending on CAR-T cell therapy and associated care (inpatient: $603,001 versus $548,488 [commercial] and $502,138 [Medicare] and outpatient: $594,910 versus $583,745 [commercial] and $417,298 [Medicare]).

 Conclusions

Among patients covered by private or public insurance, we observed higher average spending on CAR-T cell therapies delivered in the inpatient setting, but higher average spending on CAR-T cell therapies and associated care among those receiving infusions in the outpatient setting. Although transitioning CAR-T cell therapy infusions to the outpatient setting has been proposed as a strategy to produce cost-savings, this shift may result in increased hospitalizations and subsequent health plan and enrollee spending. As clinical evidence indicates long-term remission and survival, future research is needed to understand how pricing (e.g., value-based pricing), manufacturing, (e.g., “off the shelf” production), and provider strategies (e.g., shifting care settings to maximize reimbursement) could impact the affordability of and access to CAR-T cell therapies.

Shelley Anne Jazowski, PhD, MPH: No relevant conflicts of interest to declare.